drugset / Trial / NCT04706741
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).
Timeline
- Start
- 2022-01-06
- Primary completion
- 2022-08-25
- Completion
- 2022-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | — | Subcutaneous |
| Background | Prednisolone | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |